ART Advanced Research Technologies Appoints Two Additional Sales Professionals to Lead North American Commercialization of Optix
January 17 2008 - 7:05AM
Marketwired
MONTREAL, QUEBEC (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
that Mr. Matthew Smith, Ph.D., and Mr. Sean Pitts have joined the
Company as Senior Area Sales Manager and Area Sales Manager
respectively, for the North American preclinical imaging market
segment.
Dr. Smith earned his Ph.D. from the University of Delaware,
where his research focus was on nuclear magnetic resonance imaging
(NMR) applied to biological systems. Prior to joining ART, he was
Area Sales Manager at VisualSonics, Inc. and held sales management
roles at Varian, Inc. and Chemagnetics, Inc., which provide him an
excellent background to support imaging and high technology sales
at ART. Dr. Smith will fulfill the role of Senior Area Sales
Manager focusing his efforts in Eastern North America.
With over 12 years of top-level sales experience behind him, Mr.
Pitts will lead the implementation of ART's commercial strategy in
Western North America as well as oversee ART's channel development
for preclinical imaging, in the Asia-Pacific region. Prior to
joining ART, Mr. Pitts was Area Sales Manager for VisualSonics,
Inc., a leader in ultrasound imaging, and has held various sales
roles at Millipore Corporation and Stratagene, both leaders in
their respective fields of research.
In late 2007, ART announced its intent to commercialize the
Optix� preclinical imaging product portfolio direct in North
America and Europe. "We are very pleased with our ability to
recruit people of Matthew Smith's and Sean Pitts' caliber to the
ART team. Their strong track record of selling imaging
instrumentation and supporting a high technology user base gives us
full confidence that they can represent the Optix product
effectively in North America," said Sebastien Gignac, President and
CEO of ART.
Dino DiCamillo, ART's Vice President of Global Sales and
Marketing, Preclinical Imaging, added: "The appointment of Matthew
Smith and Sean Pitts fulfills our obligation to ART's user base and
enables the preclinical imaging team to execute our commercial
strategy of distributing ART's preclinical molecular imaging
solution direct to the customers in North America and Europe. It is
our intention to provide world-class service and application
assistance to enable our Optix users to fully utilize the potential
of optical imaging in their research programs."
Dr. Smith commented: "I am very excited to take on this
opportunity to execute on ART's commercial effort in preclinical
imaging. My prior experience in helping build and develop a
preclinical imaging business will translate well into the optical
imaging field. I look forward to continuing to advance ART's market
position and implement a successful team to support our customer
base." Mr. Pitts added: "I am excited to join the ART commercial
team. My career has afforded me the opportunity to participate in
the commercialization of new and exciting technology and I see the
same opportunity to develop molecular optical imaging at ART".
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART and is used by industry and
academic leaders worldwide. The SoftScan� optical breast imaging
device is designed to improve the diagnosis and treatment of breast
cancer. ART is commercializing the SoftScan optical medical imaging
device via a global strategic alliance with GE Healthcare, a world
leader in mammography and imaging. Finally, the Fenestra� line of
molecular imaging contrast products provide image enhancement for a
wide range of preclinical Micro CT applications allowing scientists
to see greater detail in their imaging studies, with potential
extension into other major imaging modalities. The distribution of
the Fenestra line of imaging contrast agents is made through GE
Healthcare Bio-Science KK in Japan and is sold directly by the
Company in the rest of the world. ART's shares are listed on the
TSX under the ticker symbol ARA. For more information on ART, visit
our website at www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer (514) 832-0777 Email: jbedard@art.ca ART
Advanced Research Technologies Inc. Dino DiCamillo, Vice President
of Global Sales & Marketing for Preclinical Imaging (514)
832-0777 Email: ddicamil@art.ca Website: www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024